VivoSeq
Oncology

Central Nervous System Tumor

1

Pipeline Programs↗

4

Active Trials↗

3

Companies Involved↗

Central Nervous System Tumor is an early-stage landscape with 1 program across 3 companies. The most active players are Binhui Biopharmaceutical Co., Ltd., Sanofi, Eisai.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

77/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Binhui Biopharmaceutical Co., Ltd.

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalEisai logo

Eisai

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Tozuleristide

Blaze Bioscience Inc.

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

17

clinical trials

Completed10 · 59%
Recruiting4 · 24%
Terminated3 · 18%

Clinical Trials

Trial Activity

17 trials

Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors
Recruiting·WWashington University School of Medicine·Phase 1·NCT03988283·7 enrolled
OH2 Oncolytic Viral Therapy in Central Nervous System Tumors
Recruiting·BBinhui Biopharmaceutical Co., Ltd.·Phase 1/2·NCT05235074·28 enrolled
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
Recruiting·CCentre Leon Berard·Phase 1/2·NCT07243470·70 enrolled
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Recruiting·National Cancer Institute (NCI)·Phase 1/2·NCT06161519·146 enrolled
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Completed·National Cancer Institute (NCI)·Phase 1·NCT02415153·29 enrolled
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Completed·National Cancer Institute (NCI)·Phase 1·NCT01538095·37 enrolled
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
Completed·PPediatric Brain Tumor Consortium·Phase 1·NCT01975116·18 enrolled
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Completed·PPediatric Brain Tumor Consortium·Phase 1·NCT01158300·28 enrolled
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors
Completed·—·Phase 1·NCT03565367·9 enrolled
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
Completed·National Cancer Institute (NCI)·Phase 1/2·NCT00095940·52 enrolled
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Completed·Sanofi logoSanofi·Phase 1/2·NCT01751308·39 enrolled
Indocyanine Green for Central Nervous System Tumors
Completed·—·Phase 1/2·NCT02710240·336 enrolled
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Completed·Eisai logoEisai·Phase 1/2·NCT03245151·64 enrolled
A Phase 2 Study of Fluorescence Detection of Adult Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System
Completed·—·Phase 2·NCT04743310·50 enrolled
Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
Terminated·IIndiana University·Phase 2·NCT02885324·4 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)